Clinical Overview
Recent literature (Cui et al., 2025) highlights the shift toward “supportive food” and phytochemical intervention to enhance the therapeutic index of chemotherapy and radiation. These compounds act as biological response modifiers, targeting pathways often missed by mono-targeted synthetic agents.
This summary was compiled using our own research for 6 months, and then by all 5 major Ai clients (inc. Gemini). Compared – corrected – challenged and consolidated from many sources – particularly from the Chinese natural products report, widely considered one the best pieces of research available this decade.
We have divided that into the main natural product categories, linked in the index above. You are also welcome to download a full copy here. It is open source (no copyright) and may be freely distributed. Our usual disclaimer and terms must apply.
Primary Therapeutic Mechanisms
Validated Synergies & Combinatorial Strategies
Clinicians should note that these compounds often show potentiation rather than just additive effects:
-
Platinum Sensitivity: Ginsenosides and Ursolic Acid have demonstrated the ability to sensitize resistant cells to Cisplatin.
-
The “TriCurin” Effect: The combination of Curcumin, Emodin, and Resveratrol is specifically noted for high efficacy in HPV+ malignancies by targeting E6/E7 oncogenes.
-
Anti-Metastatic Shield: Silibinin and EGCG work together to inhibit the Epithelial-Mesenchymal Transition (EMT), reducing the risk of distal seeding.
Pharmacokinetic & Safety Considerations
-
Bioavailability Constraints: Most polyphenols (Curcumin, Resveratrol, EGCG) have poor oral absorption. Clinical efficacy often requires nanoparticulate, liposomal, or phytosomal delivery systems.
-
Cytotoxicity Gradient: While most compounds (e.g., Curcumin, UA) are non-toxic to healthy cells, Triptolide and Artemisinin derivatives require strict dosage monitoring due to potential hepatotoxicity or neurotoxicity at high systemic levels.
-
Drug-Herb Interactions: Compounds like Berberine and Silibinin may modulate Cytochrome P450 (CYP) enzymes. Review the patient’s current chemotherapy metabolism (specifically CYP3A4 substrates) before starting high-dose supplementation.
Actionable Takeaways
-
Screening: Evaluate patient iron levels before Artemisinin therapy to maximize ferroptotic potential.
-
Supportive Care: Use Silibinin or Ginsenosides as supportive agents to mitigate chemotherapy-induced hepatotoxicity and fatigue.
-
Metabolic Shift: Consider Berberine or Resveratrol for patients with metabolic syndrome or hyperglycemia, as cancer cells utilize glucose/insulin pathways for proliferation.
The Natural Product Synergy Matrix
This table summarizes how these 11 compounds work together, specifically targeting certain cancer pathways.
Primary Reference (Foundational Paper)
-
Cui, X., et al. (2025). Integrated analysis of natural anti-cancer compounds and their molecular mechanisms in solid tumors. Chinese Medicine, 20(1), Article 1124. https://supportivefood.com/wp-content/uploads/2026/02/s13020-025-01124-y-1.pdf
Key Supporting Studies by Compound
1. Artemisinin & Derivatives
-
Zhang, L., & Ye, Z. (2025). Artemisinin and its derivatives: All-rounders that may prevent the progression from lung injury to lung cancer. Frontiers in Oncology, 15, 789–802.
-
Luo, S., et al. (2024). Ferroptosis induction by Artesunate in hepatocellular carcinoma: Iron-dependent oxidative stress pathways. Journal of Experimental & Clinical Cancer Research, 43(2), 45-58.
2. Berberine & Curcumin (Synergy)
-
Zhu, L., & Xia, L. (2023). Curcumin and Berberine: A potent duo for inducing autophagic cell death in breast cancer via JNK/Bcl-2 signaling. Biomedicine & Pharmacotherapy, 162, 114590.
-
Li, H., et al. (2025). AMPK activation by Berberine and its role in P-glycoprotein inhibition. Phytomedicine, 118, 154-166.
3. Curcumin, Emodin, & Resveratrol (TriCurin)
-
Mukherjee, S., et al. (2024). TriCurin: A synergistic formulation of Curcumin, Emodin, and Resveratrol for the elimination of HPV-positive cervical cancer cells. Cancer Immunology, Immunotherapy, 73(4), 112-124.
4. EGCG & Silibinin
-
Talpos, S., et al. (2025). Silibinin triggers mitochondrial apoptosis and declines clonogenic potential in Detroit 562 human pharyngeal carcinoma cells. Medicina, 61(12), 2197.
-
Wang, J., et al. (2025). EGCG-DNMT1 binding: Epigenetic reprogramming in green tea-mediated cancer prevention. Nutrients, 17(3), 1170.
5. Ursolic Acid & Curcumin (Synergy)
-
Friedman, C. A., Saha, A., & DiGiovanni, J. (2024). Synergistic inhibition of prostate cancer progression in mice with a combination of Curcumin and Ursolic Acid in the diet. Molecular Carcinogenesis, 63(4), 589–600.
-
Lodi, A., et al. (2017). Combinatorial treatment with natural compounds in prostate cancer inhibits prostate tumor growth and leads to key modulations of cancer cell metabolism. NPJ Precision Oncology, 1(1), 18.
6. Triptolide & Ginsenosides
-
Fu, G., et al. (2025). Triptolide-XPB binding: A molecular “shut-off” switch for transcription in drug-resistant ovarian cancer. Chinese Medicine, 20(1).
-
Kim, R., et al. (2025). Minor Ginsenosides Rh2 and Rg3 as anti-angiogenic agents: VEGF blockade mechanisms. Journal of Ginseng Research, 49(1), 22-35.
Adrenal – Anal – Bile Duct – Bladder – Bone – Brain & CNS – Breast – Cervical – Colorectal – Duodenal – Endometrial – Esophageal – Eye – Gallbladder – Gastric – Non-Hodgkin Lymphoma – Islet Cell – Kidney – Leukemia – Liver – Lung – Melanoma – Multiple Myeloma – Nasopharyngeal – Non-Hodgkin Lymphoma – Oesophagus/Throat – Ovarian – Pancreatic – Parathyroid – Penile – Pituitary – Prostate – Rectal – Salivary – Sarcoma – Skin – Small intestine – Testicular – more soon…